News | March 04, 2008

First Implant of CRT-D with New Platform Completed

February 5, 2008 - Doctors completed the first implant of Boston Scientific’s COGNIS cardiac resynchronization therapy defibrillator (CRT-D), which reportedly represents an entirely new platform to treat heart failure.

The COGNIS was part of a multi-year research and development effort to build a devices that offers extended longevity and a number of new features to manage heart failure patients. One such feature is the SmartDelay, which is said to quickly proposes programmable device settings and enable clinicians to tailor individualized pacing therapy for their patients.

The COGNIS CRT-D is small and thinn with high-energy at 32.5 cc, and less than 10 mm thick. The COGNIS CRT-D also offers SafetyCore, a feature that in the unlikely event of a system error is designed to provide lifesaving shock therapy and basic pacing functionality.

Key features of the COGNIS CRT-D include:

- Bi-V Trigger: designed to help physicians manage heart failure patients with frequent atrial arrhythmias
- Electronic Repositioning: provides physicians with the ability to electronically select between six different configurations for stimulating the left side of the heart even after implant, which could help avoid an additional surgical procedure, the company says.
- Left Ventricle only pacing: this feature provides physicians with an additional pacing option for CRT patients

For more information: www.bostonscientific.com

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init